UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides

Author
Lynnette K Nieman, MD
Section Editor
André Lacroix, MD
Deputy Editor
Kathryn A Martin, MD

INTRODUCTION

Measurements of plasma corticotropin (ACTH) are extremely useful in the diagnosis of both Cushing's syndrome and adrenal insufficiency. In contrast, corticotropin-releasing hormone (CRH) is rarely measured in peripheral plasma or serum because the concentrations are much lower than and do not correlate well with those in the hypothalamic-hypophysial portal plasma. This is because of contribution from nonhypothalamic sources (eg, the gastrointestinal tract). The measurement of ACTH, CRH, and other related hypothalamic and pituitary peptides will be reviewed here. The approaches to the diagnosis of Cushing's syndrome and adrenal insufficiency are discussed separately. (See "Establishing the diagnosis of Cushing's syndrome" and "Diagnosis of adrenal insufficiency in adults".)

ACTH

The current commercially available two-site immunometric assays have an analytical sensitivity between 0.6 and 9 pg/mL (0.12 to 19.8 pmol/L) [1]. However, performance differs between assays and should be considered when interpreting patient results [2,3]. Furthermore, the most common platform immunoassay in use in the United States gives significantly different results in the critical range of 9 to 118 pg/mL (2 to 26.2 pmol/L) compared with a gold standard immunometric assay [4].

Normal values — Plasma corticotropin (ACTH) concentrations are usually between 10 and 60 pg/mL (2.2 and 13.3 pmol/L) at 8 AM. The values decrease during the waking hours and are usually less than 20 pg/mL (4.5 pmol/L) at 4 PM and less than 10 pg/mL (2.2 pmol/L), usually less than 5 pg/mL (1.1 pmol/L), within one hour after the usual time of falling sleep. This circadian rhythm in plasma ACTH concentrations is the cause of the parallel changes in cortisol secretion by the adrenal glands and the resulting rhythm in serum cortisol concentrations.

Interpretation — The time of day at which the sample is taken is an important determinant of the utility of the measurement of plasma ACTH, which is often best interpreted with a simultaneous measurement of serum cortisol.

In evaluating patients with adrenal insufficiency, measurements should be made in the morning, if possible, when plasma ACTH and serum cortisol concentrations are usually at their highest value (see "Diagnosis of adrenal insufficiency in adults"). However, in urgent or emergent evaluation of patients with potential adrenal insufficiency (eg, in the intensive care unit or emergency department), blood samples should be drawn at any time before administration of glucocorticoid therapy.

    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue May 27 00:00:00 GMT+00:00 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Talbot JA, Kane JW, White A. Analytical and clinical aspects of adrenocorticotrophin determination. Ann Clin Biochem 2003; 40:453.
  2. Lindsay JR, Shanmugam VK, Oldfield EH, et al. A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing's syndrome. J Endocrinol Invest 2006; 29:983.
  3. Wilkinson CW, Raff H. Comparative evaluation of a new immunoradiometric assay for corticotropin. Clin Chem Lab Med 2006; 44:669.
  4. Raff H. Immulite vs Scantibodies IRMA plasma ACTH assay. Clin Chem 2008; 54:1409.
  5. Klose M, Kofoed-Enevoldsen A, Ostergaard Kristensen L. Single determination of plasma ACTH using an immunoradiometric assay with high detectability differentiates between ACTH-dependent and -independent Cushing's syndrome. Scand J Clin Lab Invest 2002; 62:33.
  6. Orth DN. Adrenocorticotropic hormone (ACTH). In: Methods of Hormone Radioimmunoassay, Jaffe BM, Behrman HR (Eds), Academic Press, Inc., New York 1979. p.245.
  7. Besser GM, Orth DN, Nicholson WE, et al. Dissociation of the disappearance of bioactive and radioimmunoreactive ACTH from plasma in man. J Clin Endocrinol Metab 1971; 32:595.
  8. Pfohl B, Sherman B, Schlechte J, Stone R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985; 42:897.
  9. Fukata J, Naitoh Y, Usui T, et al. Two-site immunoradiometric assay for adrenocorticotrophin: a cautionary study about the reactivity to its precursor molecules. Endocrinol Jpn 1989; 36:155.
  10. Tsuchiya K, Minami I, Tateno T, et al. Malignant gastric carcinoid causing ectopic ACTH syndrome: discrepancy of plasma ACTH levels measured by different immunoradiometric assays. Endocr J 2005; 52:743.
  11. Tsigos C, Crosby SR, Gibson S, et al. Proopiomelanocortin is the predominant adrenocorticotropin-related peptide in human cerebrospinal fluid. J Clin Endocrinol Metab 1993; 76:620.
  12. Raff H, Findling JW, Wong J. Short loop adrenocorticotropin (ACTH) feedback after ACTH-(1-24) injection in man is an artifact of the immunoradiometric assay. J Clin Endocrinol Metab 1989; 69:678.
  13. Nicholson WE, DeCherney GS, Jackson RV, et al. Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. J Clin Endocrinol Metab 1983; 57:1263.
  14. Orth DN, Mount CD. Specific high-affinity binding protein for human corticotropin-releasing hormone in normal human plasma. Biochem Biophys Res Commun 1987; 143:411.
  15. Behan DP, Linton EA, Lowry PJ. Isolation of the human plasma corticotrophin-releasing factor-binding protein. J Endocrinol 1989; 122:23.
  16. Sasaki A, Shinkawa O, Margioris AN, et al. Immunoreactive corticotropin-releasing hormone in human plasma during pregnancy, labor, and delivery. J Clin Endocrinol Metab 1987; 64:224.
  17. Ellis MJ, Livesey JH, Donald RA. Circulating plasma corticotrophin-releasing factor-like immunoreactivity. J Endocrinol 1988; 117:299.
  18. Campbell EA, Linton EA, Wolfe CD, et al. Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition. J Clin Endocrinol Metab 1987; 64:1054.
  19. Makrigiannakis A, Zoumakis E, Margioris AN, et al. The corticotropin-releasing hormone (CRH) in normal and tumoral epithelial cells of human endometrium. J Clin Endocrinol Metab 1995; 80:185.
  20. Salminen-Lappalainen K, Laatikainen T. Binding of corticotropin-releasing hormone (CRH) in maternal and fetal plasma and in amniotic fluid. Clin Chim Acta 1990; 195:57.
  21. Goland RS, Conwell IM, Warren WB, Wardlaw SL. Placental corticotropin-releasing hormone and pituitary-adrenal function during pregnancy. Neuroendocrinology 1992; 56:742.
  22. Linton EA, Perkins AV, Woods RJ, et al. Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy. J Clin Endocrinol Metab 1993; 76:260.
  23. Suda T, Tomori N, Yajima F, et al. Immunoreactive corticotropin-releasing factor in human plasma. J Clin Invest 1985; 76:2026.
  24. Sasaki A, Shinkawa O, Yoshinaga K. Placental corticotropin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans. J Clin Invest 1989; 84:1997.
  25. Jeske W, Soszyński P, Rogoziński W, et al. Plasma GHRH, CRH, ACTH, beta-endorphin, human placental lactogen, GH and cortisol concentrations at the third trimester of pregnancy. Acta Endocrinol (Copenh) 1989; 120:785.
  26. Allolio B, Hoffmann J, Linton EA, et al. Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone. Clin Endocrinol (Oxf) 1990; 33:279.
  27. Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A, et al. Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenh) 1988; 119:506.
  28. Jessop DS, Cunnah D, Millar JG, et al. A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor. J Endocrinol 1987; 113:133.
  29. Schteingart DE, Lloyd RV, Akil H, et al. Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol Metab 1986; 63:770.
  30. Wilson RE, Orth DN, Nicholson WE, et al. Human gamma-lipotropin radioimmunoassay: identification of immunoreactive gamma-lipotropin in human plasma and tissue. J Clin Endocrinol Metab 1981; 53:1.
  31. Liotta AS, Suda T, Krieger DT. beta-Lipotropin is the major opioid-like peptide of human pituitary and rat pars distalis: lack of significant beta-endorphin. Proc Natl Acad Sci U S A 1978; 75:2950.
  32. Jackson RV, DeCherney GS, DeBold CR, et al. Synthetic ovine corticotropin-releasing hormone: simultaneous release of proopiolipomelanocortin peptides in man. J Clin Endocrinol Metab 1984; 58:740.
  33. Usategui R, Oliver C, Vaudry H, et al. Immunoreactive alpha-MSH and ACTH levels in rat plasma and pituitary. Endocrinology 1976; 98:189.
  34. Bertagna XY, Stone WJ, Nicholson WE, et al. Simultaneous assay of immunoreactive beta-lipotropin, gamma-lipotropin, and beta-endorphin in plasma of normal human subjects, patients with ACTH/lipotropin hypersecretory syndromes, and patients undergoing chronic hemodialysis. J Clin Invest 1981; 67:124.
  35. Hale AC, Ratter SJ, Tomlin SJ, et al. Measurement of immunoreactive gamma-MSH in human plasma. Clin Endocrinol (Oxf) 1984; 21:139.
  36. Pettibone DJ, Mueller GP. Clonidine releases immunoreactive beta-endorphin from rat para distalis. Brain Res 1981; 221:409.
  37. Chan JS, Seidah NG, Chrétien M. Measurement of N-terminal (1-76) of human proopiomelanocortin in human plasma: correlation with adrenocorticotropin. J Clin Endocrinol Metab 1983; 56:791.
  38. Kuhn JM, Proeschel MF, Seurin DJ, et al. Comparative assessment of ACTH and lipotropin plasma levels in the diagnosis and follow-up of patients with Cushing's syndrome: a study of 210 cases. Am J Med 1989; 86:678.
  39. Raffin-Sanson ML, Massias JF, Dumont C, et al. High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 1996; 81:4272.
  40. Gibson S, Ray DW, Crosby SR, et al. Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab 1996; 81:497.